Carbonyl and oxidative stress in patients with breast cancer - Is there a relation to the stage of the disease?

Neoplasma

Volumn 54, Issue 3, 2007, Pages 219-224

  Tesarova P ^a   Kalousova M ^a   Trnkova B ^a   Soukupova J ^a   Argalasova S ^a   Mestek, O ^b   Petruzelka L ^a   Zima, T ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Advanced glycation end products; Advanced oxidation protein products; Breast cancer; Carbonyl stress; Carboxymethyllysine; Oxidative stress

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; AROMATASE INHIBITOR; CARBONYL DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN; DRUG DERIVATIVE; ESTROGEN; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CHEMICAL STRESS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PROGNOSIS; PROTEIN CARBONYLATION;

BLOOD PROTEINS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MIDDLE AGED; NEOPLASM STAGING; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROGNOSIS; PROTEIN CARBONYLATION; RECEPTOR, ERBB-2;

EID: 34347241744     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. KALOUSOVA M, ZIMA T, TESAR V et al. New markers in advanced damage by oxidative and carbonyl stress. Sborn Lék 2001, 102: 465-472 (In Czech)
2. KALOUSOVA M, HODKOVA M, KAZDEROVA M, et al. Soluble receptor for advanced glycation end products (sRAGE) in patients with decreased renal function. Am J Kidney Dis 2006, 47: 406-411. (Pubitemid 43255173)
3. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLEREBLANDIN C. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49: 1304-1313.
4. MIYATA T, VAN YPERSELE DE STRIHOU C, KUROKAWA K, et al. Alterations in nonenzymatic biochemistry in uramia: origin and significance of "carbonyl stress" in longterm uremic complications. Kidney Int. 1999, 55: 389-399.
5. MUNCH G, KIES R, WESSEL A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997, 35: 669-677 (Pubitemid 27453364)
6. SCHMIDT AM, YAN SD, YAN SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108: 949-955.
7. BUCCIARELI LG, WENDT T, RONG L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: Implications for homeoastasis and chronic disease. Cell.Mol.Life Sci 2002, 59: 1117-1128.
8. BIERHAUS A, HUMPERT P M, MORCOS M, WENDT T, et al. Uderstanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005, 83: 876-886. (Pubitemid 41598688)
9. EVANS MD, DIZDAROGLU M, COOKE MS. Oxidative DNA damage and disease: induction, repair and significance. Mutation Res 2004, 567: 1-61. (Pubitemid 39162992)
10. KANG D, HAMASAKI N. Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes, and cancer. Curr. Med. Chem 2005, 12: 429-441.
11. VAN HEIJST JW, NIESSEN HW, HOEKMAN K, et al. Advanced glycation end products in human cancer tissues: detection of N epsilon-(carboxymethyl)lysine and argpyrimidine. Ann. N.Y. Acad. Sci. 2005, 1043: 725-733.
12. HENLE T, DEPPISCH R, BECK W, et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogenity of AGE compounds. Nephrol Dial Transplant 1999, 14: 1968-1975.
13. ALTMAN,DG: Practical statistics for medical research. Chapman & Hall, Boca Raton, 1994, 347 pp.
14. TAGUCHI A, BLOOD D,C, DEL TORO G, et al. Blockade of RAGE-amphoterin signalling suppreses tumor growth and metastases, Nature 2000, 405: 354-360.
15. KUNIYASU H, CHIHARA Y, TAKAHASHI T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with mestatsis of colorectal cancer, Oncol. Reports 2003, 10: 445-448.
16. KUNIYASU H, CHIHARA Z, KONDO H. Differential effects between Amphoterin and Advanced glycation end products on collon cancer cells. Int J Cancer 2003, 104: 722-1721
17. KUNIYASU H, OUE N, WAKIKAWA A et al. Expression of receptors for advanced glycation end- products (RAGE) is closely a ssociated with invasive and metastatic activity of gastric cancer. J. Pathol 2002, 196: 163-170.
18. HIRATA K,TAKADA M,SUZUKI Y, et al. Expression of receptor fora Advanced glycation end products (RAGE) in human biliary cance cells. Hepatogastroenterology 2003, 50: 1205-1207.
19. ISHIGURO H, NAKAIGAWA N, MIYOSHI Y., et al. Receptor for advanced glycation end products (RAGE) and its ligand amphotherin are overexpressed and associated with protate cancer development. Prostate 2005, 64: 92-100.
20. TAKADA M, HIRATA K, AJIKI T, et al. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pankreatic cancer cells. Hepato-Gastroenterology 2004, 51: 928-930.
21. SCHRAML P, BENDIK I, LUDWIG CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and nonsmall cell lung carcinoma. Cancer Res 1997, 57: 3669-3671.
22. BARTLING B, HOFMANN HS, WEIGLE B, et al. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005, 26: 293-301.
23. BARTLING B, DEMLING N, SILBER,RE, et al. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am. J. Respir. Cell Mol. Biol. 2006, 34: 83-91.
24. HSIEH HL, SCHAFER B W, SASAKI N, et al. Expression analysii of S 100 proteins and RAGE in human tumors using tissue microarrays. Biochemical and Biophysical Research Communications 2003, 307: 375-381.
25. CERVANTES-LAUREAN D, ROBERTS MJ, JACOBSON,EL, et al. Nuclear proteasome activation and degradation of carboxymethylated histones in human keratinocytes following glyoxal treatment. Free Radic. Biol. Med. 2005, 38: 786-795.
26. ZILL H, GUNTHER R, ERBERSDOBLER HF, et al. RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem. Biophy. Res. Commun. 2001, 288: 1108-1111.
27. VALKO M, RHODES CJ, MONCOL J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006, 160: 1-40.
28. KOBIELA J, KUBASIK-JURANIEC J, STEFANIAK T, et al. The correlation of protein peroxidation with morphological changes in experimental oestradiol-induced carcinogenesis. Folia Morphol (Warsz) 2003, 62: 341-346.
29. GOLDKORN T, RAVID T, KHAN EM Life and death decisions: ceramide generation and EGF receptor trafficking are modulated by oxidative stress. Antioxid Redox Signal 2005, 7: 119-128.